Treatment variable | NoECT group | B-ECT group | Between-group differences |

Selective serotonin re-uptake inhibitors | |||

Pre-Treatment | 53% (n = 10) | 11% (n = 2) | CC = 0.41, p = 0.005 |

Follow-Up | 32% (n = 6) | 32% (n = 6) | CC < 0.001, p = 1.00 |

Serotonin and norepinephrine reuptake inhibitors | |||

Pre-Treatment | 42% (n = 8) | 58% (n = 11) | CC = 0.16, p = 0.33 |

Follow-Up | 26% (n = 5) | 37% (n = 7) | CC = 0.11, p = 0.49 |

Tricyclic antidepressants | |||

Pre-Treatment | 5% (n = 1) | 37% (n = 7) | CC = 0.36, p = 0.017 |

Follow-Up | 16% (n = 3) | 26% (n = 5) | CC = 0.13, p = 0.43 |

Noradrenergic and specific serotonergic antidepressants | |||

Pre-Treatment | 16% (n = 3) | 16% (n = 3) | CC < 0.001, p = 1.00 |

Follow-Up | 11% (n = 2) | 21% (n = 4) | CC = 0.14, p = 0.37 |

Lithium | |||

Pre-Treatment | 5% (n = 1) | 42% (n = 8) | CC = 0.40, p = 0.008 |

Follow-Up | 26% (n = 5) | 16% (n = 3) | CC = 0.13, p = 0.43 |

Anticonvulsants | |||

Pre-Treatment | 5% (n = 1) | 42% (n = 8) | CC = 0.40, p = 0.008 |

Follow-Up | 16% (n = 3) | 16% (n = 3) | CC < 0.001, p = 1.00 |

Benzodizepines | |||

Pre-Treatment | 26% (n = 5) | 68% (n = 13) | CC = 0.39, p = 0.009 |

Follow-Up | 32% (n = 6) | 26% (n = 5) | CC = 0.06, p = 0.72 |

Nonbenzodiazepine hypnotics | |||

Pre-Treatment | 53% (n = 10) | 53% (n = 10) | CC < 0.001, p = 1.00 |

Follow-Up | 26% (n = 5) | 26% (n = 5) | CC < 0.001, p = 1.00 |

Antipsychotics | |||

Pre-Treatment | 21% (n = 4) | 63% (n = 12) | CC = 0.39, p = 0.009 |

Follow-Up | 26% (n = 5) | 47% (n = 9) | CC = 0.21, p = 0.18 |

Total number of psychotropic medication | |||

Pre-Treatment | Mean = 2.37; SD = 0.96 | Mean = 4.47; SD = 1.39 | t |

Follow-Up | Mean = 2.21; SD = 0.79 | Mean = 2.36; SD = 1.57 | t |

Number of ECT treatments | - | Mean = 8.58; SD = 2.36 | - |